Search
An in-depth investigation of gene regulation and cell populations at sites of fetal blood-cell production provides clues as to why children with Down’s syndrome are predisposed to developing leukaemia.
Pineal parenchymal tumors are rare neoplasms for which evidence-based treatment recommendations are lacking. These tumors vary in biology, clinical characteristics, and prognosis, requiring treatment that ranges from surgical resection alone to intensive multimodal antineoplastic therapy.
Our international team highlights issues with efficacy reports in several studies on DMG with the new drug ONC201.
KMT2A-rearranged acute lymphoblastic leukaemia (ALL) represents a high risk subtype of childhood ALL. Historical treatment strategies have comprised of intensification with conventional chemotherapy. However, outcomes have remained consistently poor compared to the advances that have been seen for other ALL subtypes, particularly for infants diagnosed before their first birthday
The WA Kids Cancer Centre has a suite of world-leading research projects to unlock new treatments for childhood cancers.
The Kids Research Institute Australia’s cancer researchers will use funds raised in the name of a brave three-year-old girl to launch a new assault on the devastating form of childhood cancer which took her life.
A The Kids Research Institute Australia researcher will investigate new ways to harness the body’s own immune system to fight melanoma, thanks to Cancer Council WA funding.
Preclinical research from the WA Comprehensive Kids Cancer Centre has revealed a promising new strategy to protect bone health in children with high-risk B-cell acute lymphoblastic leukaemia (B-ALL), showing that actively rebuilding bone may deliver faster and more effective protection against debilitating fractur
Valuable support from the Raine Medical Research Foundation’s 2025 grant round will power four new research projects at The Kids Research Institute Australia.
A landmark study led by Dr Hetal Dholaria, The Kids Research Institute Australia researcher and Perth Children’s Hospital Oncologist, has confirmed that a “wait and watch” approach for newborns diagnosed with neuroblastoma is not only safe, but effective over the long term.